Ardelyx, Inc.

NasdaqGM:ARDX

Market Cap

USD 882.85 M

Share Price

USD 3.69

Avg Daily Volume

5,353,574

Change (1 day)

0.00%

Change (1 year)

-43.23%

Change (YTD)

-27.22%

Ardelyx, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -48.73 M

Ardelyx, Inc. Free Cash Flow is USD -48.73 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -39.93% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Ardelyx, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -81.12 M, a -7.56% change year over year.
  • Ardelyx, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -87.76 M, a -35.96% change year over year.
  • Ardelyx, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -137.04 M, a 34.64% change year over year.
  • Ardelyx, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -101.78 M, a 20.17% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities
Market news
Loading...
NasdaqGM: ARDX

Ardelyx, Inc.

CEO Mr. Michael G. Raab
IPO Date June 19, 2014
Location United States
Headquarters 400 Fifth Avenue
Employees 395
Sector 🏥 Health Care
Industries
Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Similar companies

BMRN

BioMarin Pharmaceutical Inc.

USD 55.17

1.98%

4151.T

Kyowa Kirin Co., Ltd.

USD 16.88

-1.46%

ABBOTINDIA.NS

Abbott India Limited

USD 408.73

5.97%

002422.SZ

Sichuan Kelun Pharmaceutical Co., Ltd.

USD 4.99

2.33%

1SXP.F

SCHOTT Pharma AG & Co. KGaA

USD 33.16

0.85%

688336.SS

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

USD 7.44

-0.33%

1513.HK

Livzon Pharmaceutical Group Inc.

USD 3.74

1.90%

0867.HK

China Medical System Holdings Limited

USD 1.53

0.16%

002773.SZ

Chengdu Kanghong Pharmaceutical Group Co., Ltd

USD 3.99

1.27%

GLAND.NS

Gland Pharma Limited

USD 20.84

-0.35%

000623.SZ

Jilin Aodong Pharmaceutical Group Co., Ltd.

USD 2.38

1.05%

600062.SS

China Resources Double-Crane Pharmaceutical Co.,Ltd.

USD 2.60

0.36%

603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

USD 1.54

2.72%

CONCORDBIO.NS

Concord Biotech Limited

USD 21.33

1.65%

002019.SZ

Yifan Pharmaceutical Co., Ltd.

USD 1.79

-0.84%

9989.HK

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

USD 0.67

-0.01%

002755.SZ

Beijing Aosaikang Pharmaceutical Co., Ltd.

USD 2.21

0.24%

300294.SZ

China Resources Boya Bio-pharmaceutical Group Co., Ltd.

USD 3.62

0.08%

NEULANDLAB.NS

Neuland Laboratories Limited

USD 141.78

1.58%

FAE.MC

Faes Farma, S.A.

USD 5.31

0.81%

LLY

Eli Lilly and Company

USD 775.45

-2.47%

ABBV

AbbVie Inc.

USD 182.31

-2.40%

RO.SW

Roche Holding AG

USD 347.50

0.20%

AZN.L

AstraZeneca PLC

USD 140.24

0.73%

MRK

Merck & Co., Inc.

USD 79.10

0.34%

TMO

Thermo Fisher Scientific Inc.

USD 408.28

-0.93%

AMGN

Amgen Inc.

USD 277.13

-0.71%

PFE

Pfizer Inc.

USD 24.19

-0.21%

GILD

Gilead Sciences, Inc.

USD 110.67

2.83%

SAN.PA

Sanofi

USD 96.65

0.37%

BMY

Bristol-Myers Squibb Company

USD 46.35

-0.64%

4519.T

Chugai Pharmaceutical Co., Ltd.

USD 51.91

-1.13%

GSK.L

GSK plc

USD 19.28

0.69%

COR

Cencora, Inc.

USD 299.42

0.96%

REGN

Regeneron Pharmaceuticals, Inc.

USD 521.00

0.00%

600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

USD 7.24

-0.32%

4502.T

Takeda Pharmaceutical Company Limited

USD 30.16

-0.03%

HLN.L

Haleon plc

USD 5.19

0.12%

4568.T

Daiichi Sankyo Company, Limited

USD 22.78

-0.29%

UCB.BR

UCB SA

USD 199.41

0.97%

3692.HK

Hansoh Pharmaceutical Group Company Limited

USD 3.71

-0.01%

DIVISLAB.NS

Divi's Laboratories Limited

USD 77.89

0.89%

INSM

Insmed Incorporated

USD 99.49

-2.21%

TEVA.TA

Teva Pharmaceutical Industries Limited

USD 16.97

-0.56%

600436.SS

Zhangzhou Pientzehuang Pharmaceutical., Ltd

USD 27.94

-0.23%

FME.DE

Fresenius Medical Care AG & Co. KGaA

USD 56.59

0.66%

WST

West Pharmaceutical Services, Inc.

USD 218.87

-0.06%

SMMT

Summit Therapeutics Inc.

USD 20.60

-3.38%

CIPLA.NS

Cipla Limited

USD 17.58

-0.50%

TORNTPHARM.NS

Torrent Pharmaceuticals Limited

USD 39.09

3.96%

StockViz Staff

June 28, 2025

Any question? Send us an email